Certara (NASDAQ:CERT) Given "Market Perform" Rating at JMP Securities

Certara (NASDAQ:CERT - Get Free Report)'s stock had its "market perform" rating reiterated by analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports.

Several other equities research analysts have also recently issued reports on CERT. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. William Blair reiterated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays reduced their target price on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird raised their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, KeyCorp upped their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.17.

Certara Stock Performance

NASDAQ:CERT traded down $1.21 during trading hours on Tuesday, reaching $11.57. The company had a trading volume of 1,104,100 shares, compared to its average volume of 1,257,622. Certara has a 52 week low of $8.64 and a 52 week high of $17.81. The firm's 50 day moving average price is $11.70 and its 200-day moving average price is $11.66. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -57.86, a PEG ratio of 9.29 and a beta of 1.57.

Hedge Funds Weigh In On Certara

Several hedge funds have recently bought and sold shares of the business. Kopion Asset Management LLC increased its stake in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after buying an additional 175,005 shares during the period. Principal Financial Group Inc. lifted its stake in Certara by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock worth $5,660,000 after acquiring an additional 15,739 shares during the period. Vontobel Holding Ltd. bought a new position in Certara during the 4th quarter worth about $1,295,000. Barclays PLC raised its holdings in shares of Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after purchasing an additional 46,880 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Certara in the 4th quarter worth approximately $3,628,000. Institutional investors own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.